Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Current Leases (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Current Leases data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Current Leases rose 11.57% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, up 11.57%, while the annual FY2025 figure was $2.7 million, 11.57% up from the prior year.
  • Current Leases reached $2.7 million in Q4 2025 per TNGX's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.1 million in Q3 2025 and bottomed at $629000.0 in Q2 2022.
  • Average Current Leases over 5 years is $2.0 million, with a median of $2.1 million recorded in 2023.
  • Peak YoY movement for Current Leases: dropped 28.48% in 2022, then surged 187.28% in 2023.
  • A 5-year view of Current Leases shows it stood at $1.5 million in 2021, then rose by 17.76% to $1.8 million in 2022, then increased by 17.63% to $2.1 million in 2023, then grew by 17.87% to $2.5 million in 2024, then increased by 11.57% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $2.7 million in Q4 2025, $3.1 million in Q3 2025, and $2.5 million in Q2 2025.